Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Active, not recruiting · Phase 2 · NCT05280470
Conditions: Extensive-stage Small-cell Lung Cancer
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 18
- Sites paid
- 22
- Planned or actual enrollment
- 187
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- Ifinatamab Deruxtecan (I-DXd) (drug)
- Dates
- Started 2022-03-09; completion 2026-12-15
- Results posted
- Not yet
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum of 3 prior lines of therapy (Part 1) and a minimum of two previous lines of systemic therapy (Part 2). This study will also investigate I-DXd anti-tumor activity in this population.
From ClinicalTrials.gov, last updated 2026-02-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $1.1M in research payments for this study in 2025 (544 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric S. Schaefer, M.D. Hematology & Oncology · Rogers, AR
- Yuanbin Chen, MD Medical Oncology · Orlando, FL
- Alberto Chiappori, MD Medical Oncology · Tampa, FL
- Estelamari Rodriguez, MD Hematology & Oncology · Miami, FL
- Hema M. Vankayala, MD Hematology & Oncology · Fleming Island, FL
- Jacob M. Sands, MD Hematology & Oncology · Burlington, MA
- Christine L. Hann, M.D., PH.D. Hematology & Oncology · Baltimore, MD
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Saiama N. Waqar, MD Medical Oncology · Saint Louis, MO
- Neal E. Ready, MD Medical Oncology · Durham, NC
- Donna M. Mcnamara, MD Medical Oncology · Hackensack, NJ
- Kristen R. Spencer, D.O. Medical Oncology · New Brunswick, NJ
- Charles M. Rudin, M.D., PH.D. Hematology & Oncology · New York, NY
- Balazs Halmos, MD Hematology & Oncology · Cleveland, OH
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Leonardo Forero, MD Medical Oncology · Amarillo, TX
- Woondong Jeong, MD Hematology & Oncology · Tomball, TX
- Rafael Santana Davila, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $367,183
- Moffitt Cancer Center $156,105
- Johns Hopkins University $141,456
- Ascension St Vincent's Riverside, FL $71,023
- Duke University $60,254
- Washington University $50,874
- University of Miami $46,497
- Sarah Cannon Research Institute $44,551
- University of Washington Medical Ctr, WA $32,680
- Biomedical Research Alliance of New York LLC $31,635
- Highlands Oncology Group $29,192
- Cancer and Hematology Centers of Western Michigan $23,240
- Dana-Farber Cancer Institute $22,162
- Henry Ford Health Hospital, MI $18,295
- Hackensack University Medical Center, NJ $10,650
- Memorial Hospital for Cancer and All $4,597
- Texas Oncology-Kingwood North $3,427
- NYU Langone Health Perlmutter Cancer Center $871
- Texas Oncology-Amarillo Cancer Center $300
- Duke University Medical Center $99
- Johns Hopkins Hospital, the, MD $57
- Duke University Hospital, NC $49
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.